Walleye Capital LLC Makes New Investment in Nektar Therapeutics $NKTR

Posted by Brenda Bartman on Jul 25th, 2026

Walleye Capital LLC bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 12,878 shares of the biopharmaceutical company’s stock, valued at approximately $927,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 210 shares in the last quarter. KBC Group NV bought a new stake in shares of Nektar Therapeutics during the first quarter worth $52,000. Headlands Technologies LLC bought a new stake in shares of Nektar Therapeutics during the second quarter worth $65,000. State of Wyoming acquired a new position in shares of Nektar Therapeutics during the first quarter valued at $67,000. Finally, Integrated Wealth Concepts LLC bought a new position in Nektar Therapeutics in the first quarter valued at about $68,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Trading Up 2.0%

Shares of NKTR opened at $70.72 on Friday. The stock has a market cap of $2.39 billion, a P/E ratio of -8.40 and a beta of 1.13. Nektar Therapeutics has a 1 year low of $21.02 and a 1 year high of $109.00. The stock’s 50-day moving average price is $65.37 and its two-hundred day moving average price is $65.44.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). The company had revenue of $10.86 million during the quarter, compared to the consensus estimate of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. As a group, equities analysts forecast that Nektar Therapeutics will post -9.37 EPS for the current year.

Wall Street Analysts Forecast Growth

NKTR has been the subject of a number of research reports. BTIG Research lifted their price objective on Nektar Therapeutics from $151.00 to $178.00 and gave the stock a “buy” rating in a research report on Monday, April 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Tuesday, June 2nd. Piper Sandler raised their price objective on shares of Nektar Therapeutics from $105.00 to $192.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. HC Wainwright lifted their target price on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Finally, Citigroup upped their target price on shares of Nektar Therapeutics from $123.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Nektar Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $150.00.

Check Out Our Latest Research Report on Nektar Therapeutics

Insider Buying and Selling

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 5,681 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total value of $397,670.00. Following the completion of the sale, the insider owned 9,756 shares of the company’s stock, valued at approximately $682,920. This represents a 36.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 10,000 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.32, for a total transaction of $603,200.00. Following the completion of the sale, the chief executive officer owned 65,045 shares in the company, valued at approximately $3,923,514.40. This trade represents a 13.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 21,862 shares of company stock valued at $1,379,205. Corporate insiders own 2.50% of the company’s stock.

Nektar Therapeutics Company Profile

(Free Report)

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.